Literature DB >> 31993636

Time to Detection of Hepatitis C Virus Infection With the Xpert HCV Viral Load Fingerstick Point-of-Care Assay: Facilitating a More Rapid Time to Diagnosis.

Jason Grebely1, Beth Catlett1,2, Indika Jayasinghe1, Heather Valerio1, Behzad Hajarizadeh1, Andrey Verich1, Philip Cunningham1,2, Marianne Martinello1, Shane Tillakeratne1, David Silk1, Gregory J Dore1, Tanya L Applegate1.   

Abstract

BACKGROUND: Xpert HCV Viral Load Fingerstick assay (Xpert HCV VL FS) is a point-of-care test quantifying HCV RNA in <1 hour, enabling same-visit diagnosis and treatment.
METHODS: This study evaluated time to HCV RNA detection using the Xpert HCV VL FS assay. Fingerstick whole-blood samples were collected from participants in an observational cohort in Australia.
RESULTS: In May 2018-2019, 1468 participants were enrolled, 1426 had Xpert HCV VL FS testing performed, and 1386 had a valid result. HCV RNA was detected in 23% (325/1386). Among people with undetectable HCV RNA (n = 1061), median time to result was 57 minutes. Among people with detectable HCV RNA (n = 325), median time to HCV RNA detection was 32 minutes and 80% (261/325) had a detectable HCV RNA result in ≤40 minutes. Median time to HCV RNA detection was dependent on HCV RNA level.
CONCLUSIONS: A quicker HCV diagnosis could be achieved by monitoring the time when HCV RNA is first detected with the Xpert HCV VL FS test, rather than HCV RNA quantification, although the current platform does not allow for this. These findings could facilitate new strategies to reduce waiting times for an HCV diagnosis and improve linkage to treatment.
© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  HCV; PWID; diagnostics; rapid; testing

Year:  2020        PMID: 31993636     DOI: 10.1093/infdis/jiaa037

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  4 in total

Review 1.  Integrating Management of Hepatitis C Infection into Primary Care: the Key to Hepatitis C Elimination Efforts.

Authors:  Allison E Wang; Eric Hsieh; Barbara J Turner; Norah Terrault
Journal:  J Gen Intern Med       Date:  2022-04-28       Impact factor: 6.473

2.  Assessing Molecular Point-of-Care Testing and Dried Blood Spot for Hepatitis C Virus Screening in People Who Inject Drugs.

Authors:  Stéphane Chevaliez; Mélanie Wlassow; Johann Volant; Françoise Roudot-Thoraval; Antoine Bachelard; Lila Poiteau; Jean-Baptiste Trabut; Christophe Hézode; Anne Bourdel; Stéphanie Dominguez
Journal:  Open Forum Infect Dis       Date:  2020-05-26       Impact factor: 3.835

3.  Elbasvir and grazoprevir for hepatitis C virus genotype 1 infection in people with recent injecting drug use (DARLO-C): An open-label, single-arm, phase 4, multicentre trial.

Authors:  Jason Grebely; Phillip Read; Evan B Cunningham; Martin Weltman; Gail V Matthews; Adrian Dunlop; Mark Montebello; Marianne Martinello; Rosie Gilliver; Philippa Marks; Tanya L Applegate; Gregory J Dore
Journal:  Health Sci Rep       Date:  2020-03-15

4.  Seroprevalence of hepatitis B virus and hepatitis C virus infection among Malaysian population.

Authors:  Nor Asiah Muhamad; Rimah Melati Ab Ghani; Mohd Hatta Abdul Mutalip; Eida Nurhadzira Muhammad; Hasmah Mohamad Haris; Rozainanee Mohd Zain; Noraidatulakma Abdullah; Nor Azila Muhammad Azami; Nazihah Abd Jalal; Norliza Ismail; Nurul Ain Mhd Yusuf; Raihannah Othman; Azwa Shawani Kamalul Arifin; Mohd Shaharom Abdullah; Mohd Arman Kamaruddin; Muhammad Radzi Abu Hassan; Tahir Aris; Rahman Jamal
Journal:  Sci Rep       Date:  2020-12-03       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.